Net sales were 65,066 million yen (Year-over-Year 3.0% increase), operating income was 3,244 million yen (4.2% increase), and quarterly net income attributable to owners of parent was 2,395 million yen (2.4% increase), showing a trend of revenue and profit growth. The full-year forecast has been revised to net sales of 89,000 million yen and net income of 3,250 million yen. A share buyback was also executed. Segments include alcoholic beverages, enzyme pharmaceuticals, and real estate; expansion of overseas channels for enzyme pharmaceuticals contributed to performance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2533","jir_company_name":"Oenon Holdings, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2533-20261109-01.pdf","jir_short_summary":"Net sales were 65,066 million yen (Year-over-Year 3.0% increase), operating income was 3,244 million yen (4.2% increase), and quarterly net income attributable to owners of parent was 2,395 million yen (2.4% increase), showing a trend of revenue and profit growth. The full-year forecast has been revised to net sales of 89,000 million yen and net income of 3,250 million yen. A share buyback was also executed. Segments include alcoholic beverages, enzyme pharmaceuticals, and real estate; expansion of overseas channels for enzyme pharmaceuticals contributed to performance.","jir_summary":"### Performance Overview\nFor the cumulative third quarter, net sales were 65,066 million yen (Year-over-Year 3.0% increase), operating income was 3,244 million yen (4.2% increase), ordinary income was 3,274 million yen (1.1% increase), and quarterly net income attributable to owners of parent was 2,395 million yen (2.4% increase), maintaining a trend of rising profits. By segment, the company comprises alcoholic beverages, enzyme pharmaceuticals, real estate, and others; notably, enzyme pharmaceuticals contributed to revenue and profit growth due to strong overseas sales and expanded contract fermentation. The full-year forecasts have been revised to net sales of 89,000 million yen, ordinary income of 4,000 million yen, and net income of 3,250 million yen. The execution of a share buyback was also disclosed.\n\n### Outlook and Impact on Shareholders\nTaking into account the revision of the full-year forecast and expected gains on sales of investment securities, the year-end net income outlook was increased by 350 million yen (to 3,250 million yen). The company intends to continue efforts to achieve the mid-term plan \"NEXT100.\" The implementation of the share buyback is regarded as part of shareholder returns and may help mitigate dilution pressure. Segment-wise, continued overseas expansion of enzyme pharmaceuticals and the enlargement of contract fermentation are expected to remain drivers of profitability.","jir_financial_highlights":"Net Sales: 65,066 (YoY 4.2% increase (cumulative for Q3))\nOperating Income: 3,244 (YoY 4.2% increase)\nOrdinary Income: 3,274 (YoY 1.1% increase)\nQuarterly Net Income Attributable to Owners of Parent: 2,395 (YoY 2.4% increase)\nFull-year Net Sales: 89,000 (Same as previous forecast)\nFull-year Net Income: 3,250 (Increase of 350 million yen (versus previous forecast))","jir_category":"","jir_hashtags":"#OenonHoldings, #Earnings, #MidtermManagementPlan, #EnzymePharmaceuticals, #AlcoholicBeverages, #ShareBuyback","jir_key_figures":"Net Sales: 65,066 million yen (Year-over-Year 3.0% increase)\nOperating Income: 3,244 million yen (Year-over-Year 4.2% increase)\nQuarterly Net Income Attributable to Owners of Parent: 2,395 million yen (Year-over-Year 2.4% increase)","jir_meta_title":"Oenon Holdings, Inc. Q3 Financial Summary for FY2026\uff5cNet Sales 65,066 million yen, Revenue and Profit Growth","jir_meta_description":"Key points from Oenon Holdings, Inc.'s Q3 financial summary for the fiscal year ending December 2026: net sales 65,066 million yen (YoY +3.0%), operating income 3,244 million yen (YoY +4.2%). Full-year forecast revised to net sales of 89,000 million yen. Overseas expansion of enzyme pharmaceuticals contributed to performance.","jir_og_title":"Oenon Holdings, Inc. Q3 Financial Results\uff5cNet Sales 65,066 million yen","jir_og_description":"Achieved revenue and profit growth in the third quarter. Full-year forecasts have been revised. Overseas expansion of enzyme pharmaceuticals contributed.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1\\\",\\\"Q2\\\",\\\"Q3\\\",\\\"Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[0,0,65066,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1\\\",\\\"Q2\\\",\\\"Q3\\\",\\\"Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[0,0,3244,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Alcoholic Beverages\\\",\\\"Enzyme Pharmaceuticals\\\",\\\"Real Estate\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net sales to external customers\\\",\\\"data\\\":[59742,4259,1000,65]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Margin and Profit Structure\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Net Sales\\\",\\\"Cost of Sales\\\",\\\"SG&A\\\",\\\"Operating Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"million yen\\\",\\\"data\\\":[6566,53386,8435,3244]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Comparison of Forecast and Results\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{}}\"}]","ir_related_company":57195,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-145499","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n